A number of first-in-disease, first-in-class and first-in-modality drugs approved last year have redefined therapeutic areas, ...

Allosteric modulators bind to their target receptor outside of the active site ... chloride), which combines an M4 antagonist with an M1 agonist to reduce side effects. Neurosterix isn’t ...

Emil Franchi joins Jerry this week. Chappell Roan - exclusive Sound of 2025 interview Chappell Roan reflects on the last 12 months in an extensive chat with Jack Saunders. Your essential guide to ...